Affiliation:
1. Laboratory of Animal Physiology and Phytopharmacology, Faculty of Science , University of Dschang , Dschang , Cameroon
Abstract
Abstract
Objectives
Dexamethasone is used experimentally to induce insulin resistance and type 2 diabetes. However, data concerning the dose, the duration of treatment, and the associated comorbidities are inconsistent. The aim of this study was to compare the effects of different doses of dexamethasone and the duration of treatment necessary for the development of a model of insulin resistance that mimics the clinical condition with the associated comorbidities.
Methods
Dexamethasone was administered intramuscularly to male Wistar rats, at doses of 500 and 1,000 µg/kg/day for the subchronic treatment (eight consecutive days) and at doses of 5, 25, 50, and 100 µg/kg/day in chronic treatment (28 consecutive days). Effects on body weight, metabolism, hemodynamics, renal function, and redox status were evaluated.
Results
Both treatments induced a progressive body weight loss that was drastic in subchronic treatment, improved glucose tolerance without affecting fasting glycemia. Doses of 1,000 and 100 µg/kg were associated with hypertriglyceridemia, hypertension, and increased heart rate, cardiac and renal hypertrophy. Increased creatinemia associated with reduced creatinuria were observed in sub-chronic treatment while increased proteinuria and reduced creatinuria were noticed in chronic treatment. 1,000 µg/kg dexamethasone caused an increase in hepatic, and renal malondialdehyde (MDA) and glutathione (GSH) coupled with a reduction in catalase activity. The dose of 100 µg/kg induced a rise in GSH and catalase activity but reduced MDA levels in the kidney.
Conclusions
Doses of 1,000 µg/kg for subchronic and 100 µg/kg for chronic treatment exhibited similar effects and are the best doses to respective time frames to induce the model.
Subject
Drug Discovery,Pharmacology,General Medicine,Physiology
Reference47 articles.
1. International Diabetes Federation. IDF Diabetes Atlas 2019, 9th ed. Brussels: International Diabetes Federation. http://www.idf.org/diabetesatlas.
2. Ramachandran, S, Rajasekaran, A, Adhirajan, N. In vivo and in vitro antidiabetic activity of Terminalia paniculata bark: an evaluation of possible phytoconstituents and mechanisms for blood glucose control in diabetes. ISRN Pharmacol 2013;484675. https://doi.org/10.1155/2013/484675.
3. Oguntibeju, OO. Type 2 diabetes mellitus, oxidative stress and inflammation: examining the links. Int J Physiol Pathophysiol Pharmacol 2019;11:45–63.
4. Bigna, JJ, Nansseu, JR, Katte, J-C, Noubiap, JJ. Prevalence of prediabetes and diabetes mellitus among adults residing in Cameroon: a systematic review and meta-analysis. Diabetes Res Clin Pract 2018;137:109–18. https://doi.org/10.1016/j.diabres.2017.12.005.
5. WHO. Diabetes. Available from: https://www.who.int/news-room/fact-sheets/detail/diabetes [Accessed 10 Sept 2020].
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献